Pharming appoints Perry Calias as chief scientific officer

18 February 2015

Dutch pharma company Pharming (Euronext: PHARM) has appointed Perry Calias as chief scientific officer.

Dr Calias will have overall responsibility for the company’s new enzyme replacement therapy programs, achieving scientific milestones set in the business plan, enhancing the intellectual property portfolio and overseeing new product development.

He is a specialist in developing targeted therapies, and as senior director for Shire (LSE: SHP), he led the investigational effort for the intrathecal administration of recombinant enzymes to treat central nervous system disorders associated with lysosomal storage diseases. He is listed as an inventor on more than 30 domestic and foreign patents or applications across 18 different patent families, including mRNA therapeutics, new polyethylene glycol-linker chemistries, noninvasive ocular delivery devices, nucleic acid protecting strategies, and combination anti-angiogenic therapies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK